Soleno Therapeutics, Inc.SLNONASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank90
3Y CAGR+102.2%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+102.2%/yr
Quarterly compound
Percentile
P90
Near historical high
vs 3Y Ago
8.3x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 82.90% |
| Q3 2025 | 438.77% |
| Q2 2025 | 85.74% |
| Q1 2025 | 22.62% |
| Q4 2024 | 26.30% |
| Q3 2024 | -245.28% |
| Q2 2024 | 1.04% |
| Q1 2024 | -68.76% |
| Q4 2023 | -33.98% |
| Q3 2023 | -20.40% |
| Q2 2023 | -1.82% |
| Q1 2023 | -50.96% |
| Q4 2022 | 10.02% |
| Q3 2022 | 8.02% |
| Q2 2022 | -17.43% |
| Q1 2022 | -92.37% |
| Q4 2021 | 63.78% |
| Q3 2021 | 25.25% |
| Q2 2021 | -221.07% |
| Q1 2021 | 215.07% |
| Q4 2020 | -1.27% |
| Q3 2020 | 29.80% |
| Q2 2020 | -220.59% |
| Q1 2020 | 234.91% |
| Q4 2019 | -12.69% |
| Q3 2019 | -8.57% |
| Q2 2019 | -12.96% |
| Q1 2019 | -40.82% |
| Q4 2018 | 8.84% |
| Q3 2018 | -13.62% |
| Q2 2018 | 1.78% |
| Q1 2018 | 33.16% |
| Q4 2017 | -93.35% |
| Q3 2017 | 16.23% |
| Q2 2017 | -45.25% |
| Q1 2017 | 25.24% |
| Q4 2016 | -0.51% |
| Q3 2016 | 14.75% |
| Q2 2016 | 19.07% |
| Q1 2016 | -21.57% |